Omega-3 PUFA for Treatment of Patients With Idiopathic Oligoasthenoteratospermia
Launched by JINLING HOSPITAL, CHINA · Aug 15, 2018
Trial Information
Current as of June 04, 2025
Unknown status
Keywords
ClinConnect Summary
In the previous work, investigators found high fat diet induced gut microbiota dysbiosis can lead to low sperm motility and sperm count, and also recognised some microbes which may lead to the low sperm motility and sperm count. It is obvious that gut microbiota can influence the sperm quality. And the supplement of n-3 PUFA is significantly correlated with microbiome alpha diversity. So investigators want to collected the fecal samples from the participants, to ascertain whether the supplementation of n-3 PUFA can promote sperm parameters by improve gut microbiota ecosystem.
The potential...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of Oligoasthenoteratospermia.
- Exclusion Criteria:
- • Leukocytospermia, prostatitis, genital trauma, testicular torsion, urinary tract infections, cryptorchidism, varicocele, diabetes, inguinal and genital surgery.
- • Y chromosome microdeletion and chromosomal karyotype abnormality.
- • Extreme oligospermia.
- • Hepatobiliary diseases, kidney failure.
About Jinling Hospital, China
Jinling Hospital, located in Nanjing, China, is a prominent healthcare institution renowned for its commitment to advanced medical research and comprehensive patient care. As a key clinical trial sponsor, Jinling Hospital leverages its robust clinical expertise and state-of-the-art facilities to facilitate innovative research initiatives that aim to improve therapeutic outcomes across various medical fields. With a dedicated team of experienced researchers and healthcare professionals, the hospital fosters collaboration and adheres to rigorous ethical standards, ensuring the integrity and quality of its clinical trials while contributing to the global advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials